Regenerx Biopharmaceuticals (RGRX) Starts Presentation at LD Micro Main Event
Regenerx Biopharmaceuticals (OTC: RGRX) is a clinical-stage biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. The company's mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology. RegeneRx acquired the rights to a novel peptide from the NIH in 1999. This intellectual property for Thymosin Beta 4 (Tβ4) allowed the company to direct its focus on tissue protection and repair in multiple disease indications. For more information, visit the company's website at www.regenerx.com. About NetworkNewsWire NetworkNewsWire…







